Document is current
Any future updates will be listed below
-
Authors
Ypinga, Jan H. L.
Boonen, Lieke H.H.M.
Munneke, Marten
Jeurissen, Patrick P. T.
Ben-Shlomo, Yoav
Bloem, Bastiaan R.
de Vries, Nienke M.
Darweesh, Sirwan K. L.
- License Information
-
More Information
Article History
Received: 16 May 2025
Accepted: 1 July 2025
First Online: 15 July 2025
Competing interests
: L.H.H.M.B. and P.P.T.J. have no financial disclosures to report. The Centre of Expertise for Parkinson and Movement Disorders was supported by a grant from the Parkinson Foundation. The contributions by B.R.B., S.K.L.D., J.H.L.Y., and M.M. are part of the collaborative Proactive and Integrated Management and Empowerment in Parkinson’s Disease (PRIME) project, which is financed by the Gatsby Foundation (GAT3676) and Dutch Ministry of Economic Affairs by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public–private partnerships. The Gatsby Foundation and the Top Sector Life Sciences & Health have a seat in the advisory board of the PRIME Parkinson project but played no role in the design of the study, analysis, and interpretation of data and in writing of the manuscript. N.M.d.V. reports grants from The Netherlands Organisation for Health Research and Development (ZonMw) and The Michael J Fox Foundation. B.R.B. currently serves as Editor in Chief for Journal of Parkinson’s disease; serves on the editorial board of Practical Neurology and Digital Biomarkers; has received honoraria from serving on the scientific advisory board for AbbVie, Biogen, and UCB; has received fees for speaking at conferences from AbbVie, Zambon, Roche, GE Healthcare, and Bial; and has received research support from the Netherlands Organization for Scientific Research, The Michael J. Fox Foundation, UCB, AbbVie, the Stichting Parkinson Fonds, the Hersenstichting Nederland, the Parkinson’s Foundation, Verily Life Sciences, Horizon 2020, the Topsector Life Sciences and Health, the Gatsby Foundation, and the Parkinson Vereniging. Y.B.S. has received research support from the UK Medical Research Council, Wellcome Trust, NIHR, Parkinson’s UK, Versus Arthritis, Gatsby Foundation, and Dunhill Trust, and is a recipient of a Radboud Excellence award. S.K.L.D. has received funding from the Parkinson’s Foundation (PF-FBS-2026), ZonMW (09150162010183), ParkinsonNL (P2022-07 and P2021-14), Michael J Fox Foundation (MJFF-022767) and Edmond J Safra Foundation.
